Skip to main content
Top
Published in: Rheumatology International 2/2007

01-12-2007 | Preliminary Results

Tumour necrosis factor a −308 promoter polymorphism in patients with rheumatoid arthritis

Authors: Zahra Rezaieyazdi, Jalil Tavakol Afshari, Mahnaz Sandooghi, Farnaz Mohajer

Published in: Rheumatology International | Issue 2/2007

Login to get access

Abstract

There are controversial reports that TNF-a promoter polymorphism may be an independent marker of susceptibility to rheumatoid arthritis (RA). We used Polymerase chain reaction amplification and Restriction fragment length polymorphism for analysis of the polymorphism at position -308 in promoter of TNF-α gene in 34 patients with RA and 30 healthy individuals. Distribution of TNF-genotypes in RA patients did not differ from that in controls. Moreover, there was apparent association between the -308 TNF-α polymorphism and erosions in hand x-Ray was found (P value = 0.043). We suggest that TNF-α -308 promoter polymorphism is not a genetic risk factor for RA susceptibility but may be associated with radiographic damage in rheumatoid patients.
Literature
1.
go back to reference Brinkman BM, Huizinga TW, Kurban SS, van der Velde EA, Schreuder GM, Hazes JM, et al (1997) Tumour necrosis factor alpha gene polymorphisms in rheumatoid arthritis: association with susceptibility to, or severity of, disease? Br J Rheumatol 36:516–521PubMedCrossRef Brinkman BM, Huizinga TW, Kurban SS, van der Velde EA, Schreuder GM, Hazes JM, et al (1997) Tumour necrosis factor alpha gene polymorphisms in rheumatoid arthritis: association with susceptibility to, or severity of, disease? Br J Rheumatol 36:516–521PubMedCrossRef
2.
go back to reference Feldmann M, Brennan FM, Maini RN (1996) Role of cytokines in rheumatoid arthritis. Annu Rev Immunol 14:397–440PubMedCrossRef Feldmann M, Brennan FM, Maini RN (1996) Role of cytokines in rheumatoid arthritis. Annu Rev Immunol 14:397–440PubMedCrossRef
3.
go back to reference Rodriguez-Carreon AA, Zuniga J, Hernandez-Pacheco G, Rodriguez-Perez JM, Balog A, Klausz G, et al (2004) Investigation of the prognostic value of TNF-alpha gene polymorphism among patients treated with infliximab, and the effects of infliximab therapy on TNF-alpha production and apoptosis. Pathobiology 71:274–280CrossRef Rodriguez-Carreon AA, Zuniga J, Hernandez-Pacheco G, Rodriguez-Perez JM, Balog A, Klausz G, et al (2004) Investigation of the prognostic value of TNF-alpha gene polymorphism among patients treated with infliximab, and the effects of infliximab therapy on TNF-alpha production and apoptosis. Pathobiology 71:274–280CrossRef
4.
go back to reference Aguillon JC, Cruzat A, Aravena O, Salazar L, Llanos C, Cuchacovich M. (2006) Could single-nucleotide polymorphisms (SNPs) affecting the tumour necrosis factor promoter be considered as part of rheumatoid arthritis evolution? Immunobiology 211:78–84CrossRef Aguillon JC, Cruzat A, Aravena O, Salazar L, Llanos C, Cuchacovich M. (2006) Could single-nucleotide polymorphisms (SNPs) affecting the tumour necrosis factor promoter be considered as part of rheumatoid arthritis evolution? Immunobiology 211:78–84CrossRef
5.
go back to reference Pawlik A, Florczak M, Ostanek L, Brzosko M, Brzosko I, Szklarz BG (2005) TNF-alpha−308 promoter polymorphism in patients with rheumatoid arthritis. Scand J Rheumatol 34:22–26PubMedCrossRef Pawlik A, Florczak M, Ostanek L, Brzosko M, Brzosko I, Szklarz BG (2005) TNF-alpha−308 promoter polymorphism in patients with rheumatoid arthritis. Scand J Rheumatol 34:22–26PubMedCrossRef
6.
go back to reference Barton A, Platt H, Salway F, Symmons D, Barrett E, Bukhari M, et al (2004) Polymorphisms in the tumour necrosis factor gene are not associated with severity of inflammatory polyarthritis. Ann Rheum Dis 63:280–284PubMedCrossRef Barton A, Platt H, Salway F, Symmons D, Barrett E, Bukhari M, et al (2004) Polymorphisms in the tumour necrosis factor gene are not associated with severity of inflammatory polyarthritis. Ann Rheum Dis 63:280–284PubMedCrossRef
7.
go back to reference Wilson AG, de Vries N, van de Putte LB, Duff GW (1995) A tumour necrosis factor alpha polymorphism is not associated with rheumatoid arthritis. Ann Rheum Dis 54:601–603PubMedCrossRef Wilson AG, de Vries N, van de Putte LB, Duff GW (1995) A tumour necrosis factor alpha polymorphism is not associated with rheumatoid arthritis. Ann Rheum Dis 54:601–603PubMedCrossRef
8.
go back to reference Lacki JK, Moser R, Korczowska I, Mackiewicz S, Muller W (2000) TNF-alpha gene polymorphism does not affect the clinical and radiological outcome of rheumatoid arthritis. Rheumatol Int 19:137–140PubMedCrossRef Lacki JK, Moser R, Korczowska I, Mackiewicz S, Muller W (2000) TNF-alpha gene polymorphism does not affect the clinical and radiological outcome of rheumatoid arthritis. Rheumatol Int 19:137–140PubMedCrossRef
9.
go back to reference Vinasco J, Beraun Y, Nieto A, Fraile A, Mataran L, Pareja E et al (1997) Polymorphism at the TNF loci in rheumatoid arthritis. Tissue Antigens 49:74–78PubMedCrossRef Vinasco J, Beraun Y, Nieto A, Fraile A, Mataran L, Pareja E et al (1997) Polymorphism at the TNF loci in rheumatoid arthritis. Tissue Antigens 49:74–78PubMedCrossRef
10.
go back to reference Danis VA, Millington M, Hyland V, Lawford R, Huang Q, Grennan D (1995) Increased frequency of the uncommon allele of tumour necrosis factor alpha gene polymorphism in rheumatoid arthritis and systemic lupus erythematosus. Dis Markers 12:127–133PubMed Danis VA, Millington M, Hyland V, Lawford R, Huang Q, Grennan D (1995) Increased frequency of the uncommon allele of tumour necrosis factor alpha gene polymorphism in rheumatoid arthritis and systemic lupus erythematosus. Dis Markers 12:127–133PubMed
11.
go back to reference Bayley JP, Ottenhoff TH, Verweij CL (2004) Is there a future for TNF promoter polymorphisms? Genes Immun 5:315–329PubMedCrossRef Bayley JP, Ottenhoff TH, Verweij CL (2004) Is there a future for TNF promoter polymorphisms? Genes Immun 5:315–329PubMedCrossRef
Metadata
Title
Tumour necrosis factor a −308 promoter polymorphism in patients with rheumatoid arthritis
Authors
Zahra Rezaieyazdi
Jalil Tavakol Afshari
Mahnaz Sandooghi
Farnaz Mohajer
Publication date
01-12-2007
Publisher
Springer-Verlag
Published in
Rheumatology International / Issue 2/2007
Print ISSN: 0172-8172
Electronic ISSN: 1437-160X
DOI
https://doi.org/10.1007/s00296-007-0444-0

Other articles of this Issue 2/2007

Rheumatology International 2/2007 Go to the issue

Letter to the Editor

Letter to the Editor

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine